Treating TNF Receptor Associated Periodic Fever Syndrome in End-Stage Renal Failure
Tumor necrosis factor receptor associated periodic syndrome (TRAPS) is a rare monogenic autoinflammatory disease. Its most severe manifestation is secondary amyloidosis. A 44-year-old male presented with nephrotic syndrome. Kidney biopsy was conclusive for secondary amyloidosis. The patient and his...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Case Reports in Nephrology |
| Online Access: | http://dx.doi.org/10.1155/2019/6819476 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553758138040320 |
|---|---|
| author | J. Coutinho R. S. Chorão M. Oliveira C. R. Santos |
| author_facet | J. Coutinho R. S. Chorão M. Oliveira C. R. Santos |
| author_sort | J. Coutinho |
| collection | DOAJ |
| description | Tumor necrosis factor receptor associated periodic syndrome (TRAPS) is a rare monogenic autoinflammatory disease. Its most severe manifestation is secondary amyloidosis. A 44-year-old male presented with nephrotic syndrome. Kidney biopsy was conclusive for secondary amyloidosis. The patient and his children had a history of recurrent febrile periods since infancy. All subjects were positive for a heterozygous variant of the TNFRSF1A gene, confirming TRAPS diagnosis. The patient progressed to end-stage renal failure and developed recurrent pericarditis episodes. He was started on anakinra while on hemodialysis with marked reduction of his serum amyloid A protein (SAA) levels. Meanwhile he received a cadaveric renal transplant and maintains anakinra treatment. Despite renal failure being the most feared complication of AA amyloidosis caused by TRAPS, little data is available about safety of anti-IL-1 treatment in patients with severe kidney failure. The authors report this case of a patient on dialysis treated with anakinra in which no complications were registered. Though amyloidosis is established, the authors believe containing its progression and reducing inflammatory activity can improve patient prognosis and reduce recurrence of amyloidosis in kidney transplant, as has been demonstrated in transplanted patients due to familial Mediterranean fever amyloidosis. |
| format | Article |
| id | doaj-art-7802f05a2b8f4149a01ebec74e1f922b |
| institution | Kabale University |
| issn | 2090-6641 2090-665X |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Nephrology |
| spelling | doaj-art-7802f05a2b8f4149a01ebec74e1f922b2025-02-03T05:53:20ZengWileyCase Reports in Nephrology2090-66412090-665X2019-01-01201910.1155/2019/68194766819476Treating TNF Receptor Associated Periodic Fever Syndrome in End-Stage Renal FailureJ. Coutinho0R. S. Chorão1M. Oliveira2C. R. Santos3Hospital Amato Lusitano, Castelo Branco, PortugalHospital Amato Lusitano, Castelo Branco, PortugalCentro Hospitalar Cova da Beira, Covilhã, PortugalHospital Amato Lusitano, Castelo Branco, PortugalTumor necrosis factor receptor associated periodic syndrome (TRAPS) is a rare monogenic autoinflammatory disease. Its most severe manifestation is secondary amyloidosis. A 44-year-old male presented with nephrotic syndrome. Kidney biopsy was conclusive for secondary amyloidosis. The patient and his children had a history of recurrent febrile periods since infancy. All subjects were positive for a heterozygous variant of the TNFRSF1A gene, confirming TRAPS diagnosis. The patient progressed to end-stage renal failure and developed recurrent pericarditis episodes. He was started on anakinra while on hemodialysis with marked reduction of his serum amyloid A protein (SAA) levels. Meanwhile he received a cadaveric renal transplant and maintains anakinra treatment. Despite renal failure being the most feared complication of AA amyloidosis caused by TRAPS, little data is available about safety of anti-IL-1 treatment in patients with severe kidney failure. The authors report this case of a patient on dialysis treated with anakinra in which no complications were registered. Though amyloidosis is established, the authors believe containing its progression and reducing inflammatory activity can improve patient prognosis and reduce recurrence of amyloidosis in kidney transplant, as has been demonstrated in transplanted patients due to familial Mediterranean fever amyloidosis.http://dx.doi.org/10.1155/2019/6819476 |
| spellingShingle | J. Coutinho R. S. Chorão M. Oliveira C. R. Santos Treating TNF Receptor Associated Periodic Fever Syndrome in End-Stage Renal Failure Case Reports in Nephrology |
| title | Treating TNF Receptor Associated Periodic Fever Syndrome in End-Stage Renal Failure |
| title_full | Treating TNF Receptor Associated Periodic Fever Syndrome in End-Stage Renal Failure |
| title_fullStr | Treating TNF Receptor Associated Periodic Fever Syndrome in End-Stage Renal Failure |
| title_full_unstemmed | Treating TNF Receptor Associated Periodic Fever Syndrome in End-Stage Renal Failure |
| title_short | Treating TNF Receptor Associated Periodic Fever Syndrome in End-Stage Renal Failure |
| title_sort | treating tnf receptor associated periodic fever syndrome in end stage renal failure |
| url | http://dx.doi.org/10.1155/2019/6819476 |
| work_keys_str_mv | AT jcoutinho treatingtnfreceptorassociatedperiodicfeversyndromeinendstagerenalfailure AT rschorao treatingtnfreceptorassociatedperiodicfeversyndromeinendstagerenalfailure AT moliveira treatingtnfreceptorassociatedperiodicfeversyndromeinendstagerenalfailure AT crsantos treatingtnfreceptorassociatedperiodicfeversyndromeinendstagerenalfailure |